Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03487666
Title OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Georgetown University
Indications

triple-receptor negative breast cancer

Therapies

Capecitabine + Nivolumab

Capecitabine

Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.